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 Glucocerebrosidase (GBA), an acid   -glucosidase en-
coded by the GBA gene at locus 1q21, catalyzes the lyso-
somal degradation of glucosylceramide into ceramide and 
glucose ( 1 ). Gaucher disease (GD) is caused by mutations 
in the GBA gene. GD is clinically very heterogeneous, rang-
ing from severe neonatal variants to very mild variants with 
onset at old age. The most common phenotype is the non-
neuronopathic type 1 (MIM*230800), showing almost ex-
clusive storage of glucosylceramide in tissue macrophages, 
the so-called “Gaucher cells” ( 1, 2 ). These lipid-laden mac-
rophages accumulate in various tissues, such as spleen, liver, 
bone marrow and lung, resulting in clinical symptoms of 
which cytopenia, hepatosplenomegaly, and skeletal abnor-
malities are the most prominent ( 1 ). Gaucher cells secrete 
a variety of cytokines and hydrolases ( 3–5 ). A several hun-
dred-fold elevated level of chitotriosidase is the biochemical 
hallmark of GD ( 3 ). Another biochemical characteristic of 
GD is the several hundred-fold increased plasma concen-
tration of the sphingoid base glucosylsphingosine ( 6 ). The 
sphingoid base is likely formed from accumulating gluco-
sylceramide in GBA-defi cient cells. 
 Being a low-abundant protein, GBA in leukocytes is dif-
fi cult to detect with antibodies ( 7 ). To study GBA more 
closely in leukocytes, we employed novel activity-based la-
beling probes (ABPs) that allow ultra-sensitive visualization 
of active GBA molecules ( 8–11 ). Epoxides like conduritol 
B epoxide (CBE) and cyclophellitol form a covalent bond 
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patients homozygous for the SCARB2/LIMP2 mutation W178X 
( 18 ), LIMP2 obligate carriers of the same mutation, GD pa-
tients with the GBA genotype L444P/L444P, and control sub-
jects. Fibroblasts obtained from skin biopsies were cultured in 
Dulbecco’s modifi ed Eagle’s medium supplemented with 10% 
fetal bovine serum, 2 mM  L -glutamine, 1% penicillin-streptomycin, 
100 mg/ml kanamycin sulfate, and 2.5 mg/ml Fungizone (Gibco, 
Invitrogen). Cells were harvested when confl uence was reached. 
Leukocytes were isolated from whole blood as described ear-
lier ( 18 ). 
 Monocytes were isolated with CD14 MicroBeads (Miltenyi 
Biotec) according to the manufacturer’s protocol. Isolated mono-
cytes were differentiated into macrophages during 7 days in RPMI 
medium supplemented with 10% human AB serum ( 3 ). 
 Mice 
 Mice were housed and plasma was collected according to the 
local protocol with approval from the review board of the Chris-
tian-Albrechts-University in Kiel (Germany). LIMP2-defi cient mice 
were generated as described in ( 16 ). 
 Preparation of cell lysates 
 Isolated fi broblasts, leukocytes, and macrophages were ho-
mogenized in potassium phosphate buffer [25 mM (pH 6.5), 
0.1% (v/v) Triton X-100]. Protein was quantifi ed by BCA kit 
(Thermo Scientifi c). 
 Labeling of GBA with ABPs 
 Cell homogenates were incubated with MDW941 (100 nM) in 
McIlvaine buffer [150 mM citrate-Na 2 HPO 4 (pH 5.2), 0.2% (w/v) 
sodium taurocholate, 0.1% (v/v) Triton X-100] for 30 min at 
37°C and subjected to SDS-PAGE . Fluorescent GBA on slab gels 
was visualized using a fl uorescence scanner (Typhoon variable 
mode imager, Amersham Biosciences) ( 8 ). 
 Intact fi broblasts were incubated with MDW941 (5 nM) for 
72 h, and subsequently the culture medium was collected and the 
cells were harvested. Detection of fl uorescent GBA in the culture 
medium was performed upon capture of the enzyme from 1 ml 
medium using monoclonal antibody 8E4 immobilized to Sepharose 
beads ( 25 ). 
 For fl uorescence-activated cell sorting (FACS), fi broblasts and 
macrophages were incubated with MDW933 (50 nM) for 5 h in 
the medium ( 8 ). In the case of white blood cells, leukocytes were 
collected from freshly drawn blood washed with 0.8% (w/v) am-
monium chloride solution and lysing the remaining erythrocytes . 
Leukocytes were next incubated with MDW933 (100 nM) for 
30 min in phosphate buffered saline containing 1% (w/v) BSA. 
FACS analysis was performed with a FACSCalibur (B.D. Biosci-
ence),   ex 488 nm,   em 530 nm (bandpass fi lter 30 nm) ( 8 ). 
 Western blotting 
 SDS-PAGE gels were electroblotted onto a nitrocellulose mem-
brane (Schleicher and Schuell). Membranes were blocked with 
5% skimmed milk and 0.05% Tween-20 in Tris-buffered saline 
(TBS) for 1 h at room temperature and incubated overnight with 
the primary antibodies at 4°C. Membranes were then washed 
three times with 0.01% Tween-20 in TBS and incubated with the 
appropriate IRDye conjugated secondary antibodies for 1 h at 
room temperature. After washing, detection was performed us-
ing the Odyssey® CLx infrared imaging system. 
 Measurement of in vivo GBA enzymatic activity 
 GBA enzymatic activity in intact fi broblasts, leukocytes, and 
macrophages was measured using 5-(pentafl uorobenzoylamino)
fl uorescein di-  - D -glucopyranoside (PFB-FDG) ( 26 ) (20   M for 
with the nucleophile E340 in GBA. Linking a BODIPY moi-
ety to the C6 of cyclophellitol renders an even more potent 
irreversible ABP of GBA. Different ABPs have been de-
signed by variation of the type of BODIPY (MDW941, Inhi-
body Red; and MDW933, Inhibody Green). The ABPs 
spontaneously cross membranes and allow very sensitive la-
beling of active GBA enzyme molecules in living cells ( 8 ). 
 The transport of newly formed GBA to lysosomes has been 
an enigma for a long time. GBA is known not to acquire man-
nose-6-phosphate moieties ( 12–15 ). The enzyme is not defi -
cient in fi broblasts of mucolipidosis II and III patients 
suffering from defects in the formation of mannose-6-
phosphate recognition signals ( 12 ). GBA was found to be-
come membrane bound in the endoplasmic reticulum by 
interaction with an unknown protein ( 13, 14 ). Only a few 
years ago, the receptor protein was identifi ed as lysosomal 
integral membrane protein-2 (LIMP2), one of the integral 
membrane proteins of lysosomes ( 16 ). Next, mutations in 
the scavenger receptor class B member 2 (SCARB2) gene, 
encoding LIMP2 protein, were found to cause action 
myoclonus-renal failure syndrome (AMRF) (MIM*602257), 
a fatal recessively inherited disorder characterized by glom-
erulosclerosis, progressive myoclonus epilepsy, ataxia, and ac-
cumulation of undefi ned storage material in the brain 
( 17–23 ). More recently it has become clear that not all AMRF 
patients develop renal complications ( 22, 23 ). Of interest, 
AMRF patients do not show the massive occurrence of lipid-
laden macrophages and similar pathology to GD patients ( 24 ). 
Consistently, AMRF patients also do not show elevated plasma 
chitotriosidase. These fi ndings point to cell-type-specifi c con-
sequences of LIMP2 defi ciency. Indeed, LIMP2-defi cient fi -
broblasts of AMRF patients lack GBA, whereas this appears 
not to be the case for their white blood cells ( 18 ). 
 The availability of ABPs allowing sensitive detection of 
GBA in leukocytes prompted us to study the fate of the 
enzyme in LIMP2-defi cient cells, obtained from an AMRF 
patient as well as from LIMP2-defi cient mice. We here 
report the outcome of these investigations, confi rming 
cell-type-specifi c reductions in GBA caused by LIMP2 defi -
ciency. Furthermore, we studied the consequences of 
LIMP2 defi ciency for glucosylceramide and glucosylsphin-
gosine levels, the products of hydrolysis by GBA. We here 
report the outcome and possible use in the differential di-
agnosis of AMRF and GD. 
 MATERIALS AND METHODS 
 ABPs 
 MDW941 (Inhibody Red) and MDW933 (Inhibody Green) 
were synthesized as described earlier ( 8 ). 
 Antibodies 
 The rabbit polyclonal anti-LIMP2 antibody was purchased to 
Novus Biologicals, Littleton, CO. 
 AMRF patient materials 
 Materials from donors were obtained after informed consent. 
Leukocytes and fi broblasts were obtained from LIMP2-defi cient 
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GBA in patient leukocytes was almost similar when com-
pared with cells from a healthy subject ( Fig. 1C ). 
 Western blot analysis using anti-LIMP2 antibody showed 
that LIMP2 protein was expressed at higher levels in fi bro-
blasts compared with leukocytes. LIMP2 was decreased 
in fi broblasts of AMRF carriers compared with controls 
( Fig. 1A, C ). Next, GBA was analyzed in monocyte-derived 
macrophages. Monocytes were isolated from the blood of 
an AMRF patient and a healthy subject and differentiated 
into macrophages. Detection of active GBA in homoge-
nates of the generated macrophages revealed again only a 
slight reduction of GBA in the patient’s cells ( Fig. 1D ). 
 Next, the amount of active GBA in intact cells was as-
sessed by FACS analysis. Cells were labeled with ABP 
MDW933, or their GBA activity was determined by incuba-
tion with the substrate PFB-FDG ( Fig. 2 ). In fi broblasts of 
three AMRF patients, active GBA was found to be reduced 
using ABP labeling ( Fig. 2A ). We also used the cell perme-
able substrate PFB-FDG for assessing GBA enzymatic activ-
ity ( Fig. 2B ). We checked to ascertain whether all detected 
activity could be ascribed to lysosomal GBA by preincuba-
tion with and without CBE, an irreversible inhibitor (data 
not shown ). 
 Fibroblasts of an AMRF carrier showed considerable lev-
els of active GBA. Similar experiments showed that the 
amount of active GBA was relatively high in the blood cells 
of an AMRF patient ( Fig. 2C ). Signifi cant residual GBA lev-
els (values >30%) were noted in lymphocytes, monocytes, 
and cultured macrophages of the AMRF patient, both with 
ABP labeling and PFB-FDG treatment. The same fi nding 
was made for total leukocytes from LIMP2-defi cient mice 
( Fig. 2C ). Measurement of GBA enzymatic activity in cell 
lysates using the artifi cial substrate 4-methylumbelliferyl-  -
 D -glucoside ( 30 ) gave similar results (data not shown). 
 Secretion of GBA by LIMP2-defi cient fi broblasts 
 Misrouting of GBA due to absence of LIMP2 might re-
sult in partial secretion of the enzyme to the extracellular 
space. To study this, cultured fi broblasts were labeled with 
MDW941 for 72 h and the culture medium was collected. 
GBA from the medium (1 ml) was immunoprecipitated 
with the anti-GBA monoclonal antibody (8E4) and visual-
ized by fl uorescence scanning of SDS-PAGE gels ( Fig. 3 ). 
Indeed, fi broblasts of AMRF patients demonstrated the 
presence of ABP-labeled GBA in the medium, which was 
absent in the WT and AMRF carriers. Of note, the molecu-
lar mass of GBA seen with SDS-PAGE is determined by its 
N-linked glycan composition. The enzyme was initially syn-
thesized with four high-mannose type glycans showing a 
mass of about 62 kDa with SDS-PAGE. In the Golgi appara-
tus, at least three glycans were modifi ed to sialylated com-
plex type structures rendering masses of 62–66 kDa. After 
entering the lysosome, the glycans are trimmed by local 
exoglycosidases resulting in a gradual reduction to 59 kDa 
( 31 ). Secreted enzyme largely shows a high molecular 
mass due to the presence of complex-type glycans, lacking 
the lysosomal deglycosylation. We presume that the very tiny 
amounts of lower mass bands, seen in the case of control 
fi broblasts, 40   M for leukocytes and macrophages) as substrate, 
exactly as described by Witte et al. ( 8 ). To discriminate the activ-
ity of lysosomal GBA from other   -glucosidases, samples were 
pretreated with and without 1 mM of CBE for 30 min before add-
ing the PFB-FDG. No activity was observed for fi broblasts prein-
cubated with CBE, indicating that activity in the absence of the 
inhibitor is due to GBA. 
 Fluorescence microscopy 
 Fibroblasts were cultured on glass slides. Cells were incubated 
with MDW933 (50 nM) for 2 h in medium. Next, cells were 
washed, fi xed with 3% (v/v) paraformaldehyde in PBS for 15 min, 
washed, incubated with 0.1 mM NH 4 Cl in PBS for 10 min, and 
then incubated with 3% (w/v) BSA and 10% (w/v) goat serum 
albumin in PBS for 1 h. Nuclei were stained with 4’,6-diamidino-
2-phenylindole (DAPI). The fi lter blocks used were A4 (360/40 
nm band pass excitation, 400 nm dichromatic mirror, 470/40 
nm band pass suppression) for DAPI and K3 (470–490 nm band 
pass excitation, 510 nm dichromatic mirror, 515 nm long pass 
suppression) for MDW933. Analysis was performed with multi-
spectral imaging, as described before ( 8 ). 
 Glucosylceramide and glucosylsphingosine measurements 
 Glucosylceramide and glucosylsphingosine in fi broblasts, leu-
kocytes, and plasma specimens were measured as described ear-
lier in ( 27 ) and ( 6 ), respectively. 
 Statistical analysis 
 The results were analyzed using the Student’s unpaired  t -test.  P < 
0.05 was considered signifi cant. Data were statistically analyzed using 
GraphPad Prism 6 software (Graphpad Software, San Diego, CA). 
 RESULTS 
 Detection of active GBA in fi broblasts, leukocytes, 
and macrophages 
 To detect active GBA molecules, homogenates of fi bro-
blasts from three AMRF patients (LIMP2 W178X/W178X), 
two AMRF carriers (LIMP2 W178X/WT), two control sub-
jects, and one type 2 GD patient (GBA L444P/L444P) 
were labeled with MDW941 (Inhibody Red) and subjected 
to SDS-PAGE. We demonstrated earlier that MDW941 spe-
cifi cally labels lysosomal GBA and no other retaining 
  -glucosidases in humans (GBA2 and GBA3) ( 8, 28 ). Actu-
ally, cultured fi broblasts contain no GBA3 and very little 
GBA2 ( 29 ). GBA, labeled after incubation of fi broblasts 
with MDW941, was detected by fl uorescence imaging of 
the slab gel ( Fig. 1A ). Fibroblasts of LIMP2-defi cient AMRF 
patients showed almost no active GBA. The active GBA was 
similarly reduced in cells from the type 2 GD patient. In 
the case of cells from the AMRF carrier, a normal amount 
of active GBA was detected. 
 Next, intact fi broblasts were incubated with MDW933 to 
visualize the active GBA molecules by fl uorescence micros-
copy ( Fig. 1B ). Multi-spectral imaging was used to differen-
tiate autofl uorescence from true ABP signals. In line with 
the results in  Fig. 1A , AMRF fi broblasts were found to be 
clearly defi cient in lysosomal GBA compared with the WT. 
 The fi ndings with leukocytes of an AMRF patient were 
very different from those of fi broblasts. Labeled active 
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glucosylceramide breakdown as seen in GD patients. We 
earlier documented the increase of glucosylsphingosine 
in plasma of symptomatic type 1 GD patients suffering 
from a primary defect in lysosomal GBA ( 6 ). Because 
LIMP2 defi ciency also results in a marked reduction of 
lysosomal GBA, we assumed that the same would occur in 
AMRF patients. 
 We therefore determined glucosylceramide and gluco-
sylsphingosine concentrations in the fi broblasts and 
plasma of AMRF patients as well as in the plasma of LIMP2-
defi cient mice. 
 In AMRF fi broblasts, glucosylceramide was not ele-
vated compared with the control range ( Fig. 4A ). Im-
portantly, a marked increase in glucosylsphingosine was 
noted ( Fig. 4C ). The same, although not to the same 
extent of elevation, was observed for leukocytes ( Fig. 4D ). 
We also detected elevated glucosylsphingosine levels in 
the plasma of three AMRF patients ( Fig. 4E ). No clear 
concomitant increase in glucosylceramide was observed 
as compared with the matched control ( Fig. 4B ). To fur-
ther validate the fi nding of the sphingoid base abnor-
mality, we also examined plasma of LIMP2-defi cient 
mice. Again, a clear elevation in glucosylsphingosine 
concentration was observed ( Fig. 4F ). 
fi broblasts but not AMRF fi broblasts, stem from lysosomal 
extrusion/secretion. 
 We next looked for the presence of GBA in the plasma 
of AMRF patients by measuring its enzymatic activity with 
the artifi cial substrate 4-methylumbelliferyl-  - D -glucoside 
( 30 ). We noted an increased activity (10.3 vs. 1.4 nmol of 
released 4-methylumbelliferone per milliliter of plasma 
per hour) in the case of fresh specimens from an AMRF 
patient versus a healthy subject. Importantly, the increased 
activity was only detected in freshly obtained plasma. Stor-
age of plasma, even frozen, led to inactivation of the enzy-
matic activity of GBA; in samples frozen for a long period 
at   20°C, less than 2% of the original GBA activity was 
detected. In line with the data for freshly obtained AMRF 
patient plasma, LIMP2-defi cient mice showed increased 
GBA as well (167 nmol/ml of plasma per hour vs. 22 nmol/ml 
of plasma per hour for WT mice). Given the loss of en-
zyme activity in plasma, measurement of plasma GBA ac-
tivity is in practice not a very reliable test to identify AMRF 
patients. 
 Lipid abnormalities in relation to LIMP2 defi ciency 
 The lack of lysosomal GBA as the result of LIMP2 
defi ciency might theoretically result in abnormalities in 
 Fig.  1. Visualization of GBA with fl uorescent ABPs MDW941 and MDW933. A: Detection of GBA in homogenates of cultured fi broblasts 
(30   g): labeling followed by SDS-PAGE and detection by fl uorescence imaging. AMRF 1, patient 1 (LIMP2 W178X/W178X); AMRF 2, 
patient 2 (LIMP2 W178X/W178X); AMRF 3, patient 3 (LIMP2 W178X/W178X); Car, carrier of AMRF (LIMP2 W178X/WT); GD, type 2 
GD patient; Rec. GBA, recombinant GBA (Cerezyme). B: Fluorescence microscopy. Fibroblasts labeled in vivo with MDW933 and DAPI 
[Upper micrograph, control fi broblasts (WT); lower micrograph, AMRF patient]. The scale bar represents 20   m. C: Detection of GBA in 
homogenates of leukocytes (50   g): labeling followed by SDS-PAGE and detection by fl uorescence imaging. D: Detection of GBA in homog-
enates of cultured macrophages (20   g): labeling followed by SDS-PAGE and detection by fl uorescence imaging. 
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GBA in their lysosomes. We demonstrate here with a vari-
ety of techniques that, indeed, white blood cells of AMRF 
patients have considerable residual GBA, in sharp contrast 
to fi broblasts. We employed newly designed ABPs that al-
low fl uorescent labeling of active GBA molecules. We fi rst 
showed that much less active GBA can be detected in 
 DISCUSSION 
 The study by Reczek et al. ( 16 ) fi rst revealed that the 
lysosomal integral membrane protein, LIMP2, mediates 
traffi cking of newly formed GBA to lysosomes. Soon after-
wards Berkovic et al. ( 17 ) demonstrated that LIMP2 defi -
ciency due to mutations in the SCARB2 gene forms the 
basis for AMRF. Independently, Balreira et al. ( 18 ) de-
scribed that mutations in the SCARB2 gene cause cell-
type-specifi c GBA defi ciency. Intriguingly, AMRF patients 
do not show the lipid-laden macrophages that characteris-
tically occur in GD patients suffering from a primary de-
fect in GBA. In GBA-defi cient GD patients, the macrophages 
are particularly prone to store glucosylceramide and to 
transform to so-called Gaucher cells ( 32 ). Gaucher cells 
produce and secrete unique marker proteins such as chi-
totriosidase and CCL18 ( 32 ). Characteristically, chitotri-
osidase is several hundred-fold higher in the plasma of 
symptomatic GD patients ( 3, 33 ). Of interest, AMRF pa-
tients do not show elevated levels of chitotriosidase like 
GD patients ( 18, 24 ) (P. Gaspar and C. Sá Miranda , un-
published observations). This suggests that somehow mac-
rophages in LIMP2-defi cient individuals can still adequately 
degrade glucosylceramide due to the presence of suffi cient 
 Fig.  2. FACS analysis of active GBA detected with ABP MDW933 and PFB-FDG as substrate. A: Example of 
FACS analysis of fi broblasts with an ABP. Left and middle panels: primary FACS data (dotted line, not labeled 
with MDW933; solid line, labeled with MDW933 ). Right panel: representative FACS dot plot. B: Example of 
FACS analysis of fi broblast enzymatic activity toward PFB-FDG. Panels as in (A). C: Overview of detected re-
sidual active GBA by analysis of cells with an ABP and PFB-FDG. 
 Fig.  3. Partial secretion of GBA by fi broblasts. Fibroblasts were 
labeled for 72 h with MDW941. From 1 ml medium, GBA was im-
munoprecipitated with anti-GBA monoclonal antibody (8E4) im-
mobilized to Sepharose beads. The immunoprecipitate, subjected 
to SDS-PAGE and fl uorescent GBA labeled by MDW941, was visual-
ized by imaging. Lane 1, carrier (Car) of AMRF (LIMP2 W178X/
WT); lane 2, AMRF patient 1 (AMRF 1) (LIMP2 W178X/W178X); 
lane 3, carrier of AMRF (LIMP2 W178X/WT); lane 4, AMRF pa-
tient 3 (AMRF 3) (LIMP2 W178X/W178X); lane 5, control subject 
(WT) (LIMP2 WT); lane 6, recombinant GBA (Rec. GBA ). 
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as substrate for in vivo detection of GBA enzymatic activity. 
Again, FACS analysis revealed a marked defi ciency in 
AMRF fi broblasts, but considerable residual enzyme in 
white blood cell types. We next looked into the fate of 
GBA in fi broblasts of AMRF patients, observing that these 
cells abnormally secrete some active GBA to the medium 
where the enzyme rapidly loses its enzymatic activity. Labile 
GBA activity is demonstrable in freshly obtained plasma of 
homogenates of AMRF fi broblasts with an ABP . In white 
blood cells and cultured macrophages, this abnormality is 
far less striking. Next we labeled intact cells with an ABP 
and noted by FACS analysis that AMRF fi broblasts are 
markedly defi cient in active GBA. Signifi cant residual active 
GBA was again detected in lymphocytes, monocytes, and 
cultured macrophages. The same phenomenon was dem-
onstrated in an independent manner by exploiting PFB-FDG 
 Fig.  4. Glucosylceramide and glucosylsphingosine content of cells and plasma in relation to AMRF/LIMP2 
defi ciency. Glucosylceramide and glucosylsphingosine were determined as described in Materials and Meth-
ods. A: Glucosylceramide (nmol/mg total protein) in AMRF fi broblasts (n = 2). B: Glucosylceramide (nmol/
ml total protein) in human AMRF plasma specimens (n = 2). C: Glucosylsphingosine (pmol/mg total pro-
tein) in AMRF fi broblasts (n = 3). D: Glucosylsphingosine (pmol/mg total protein) in AMRF leukocytes 
(n = 1). E: Glucosylsphingosine (pmol/ml) in human AMRF plasma specimens (n = 3). F: Glucosylsphingosine 
(pmol/ml) in samples from LIMP2   /   mice (n = 3). AMRF, LIMP2-defi cient patients (LIMP2 W178X/
W178X); GD, GD patients; GD Car, GD carriers; LIMP2 +/+ , WT mice; LIMP2   /   , KO LIMP2 mice. ** P < 0.01, 
unpaired student’s  t -test ). 
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AMRF patients. The mechanism by which lysosomes of 
white blood cells acquire suffi cient GBA is presently not 
known and a topic of further investigation. It can’t be ex-
cluded that these cells possess a membrane protein other 
than LIMP2 that governs intracellular transport of GBA 
from the endoplasmic reticulum to lysosomes. Alterna-
tively, secreted GBA might be taken up by some endocy-
totic process and delivered via this secretion-recapture 
manner to lysosomes of white blood cells. 
 In lysosomes, assisted by the activator protein saposin 
C, GBA takes care of degradation of glucosylceramide ( 4 ). 
Defi ciency of GBA causes formation of glucosylceramide 
storage tubules, most prominent in macrophages. Of inter-
est, part of the accumulating glucosylceramide during GBA 
defi ciency is deacylated to the sphingoid base, glucosylsphin-
gosine, which can leave lysosomes and cells ( 6 ). Most likely, 
acid ceramidase is responsible for glucosylsphingosine for-
mation, because acid ceramidase-defi cient Farber disease fi -
broblasts have been found to be unable to synthesize 
glucosylsphingosine upon inhibition of GBA activity ( 34 ). 
 This explains the marked increase in glucosylsphin-
gosine in the plasma of GD patients. Our investigation of 
glucosylceramide and glucosylsphingosine concentrations 
in cultured fi broblasts of AMRF patients revealed that only 
the sphingoid base, glucosylsphingosine, is markedly in-
creased. Consistent with this, glucosylsphingosine is abnor-
mally high in the plasma of AMRF patients. This fi nding 
was also made with plasma specimens of LIMP2-defi cient 
mice. Apparently, in AMRF patients, cells other than mac-
rophages also form glucosylsphingosine during GBA defi -
ciency that is partly released into the circulation. 
 Our investigation renders a workfl ow for convenient 
laboratory diagnosis of AMRF prior to sequencing of the 
SCARB2 gene. If markedly increased plasma glucosyl-
sphingosine is detected in an individual in the absence of 
elevated chitotriosidase, this is an indication for AMRF . 
Measurement of GBA activity in white blood cells will not 
be very informative, but in fi broblasts enzymatic activity 
needs to be reduced to consider further the diagnosis 
AMRF. Such a diagnosis can be further substantiated with 
the sequencing of the SCARB2 gene. Demonstration of 
functional GBA defi ciency by detection of abnormally 
high glucosylsphingosine in plasma should be considered 
as an important step in identifi cation of individuals suffer-
ing from a truly functional defi ciency in LIMP2.  
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